Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

Cancer Immunology Immunotherapy

Volumn 42, Issue 5, 1996, Pages 303-309

  Reddish, Mark A ^a   MacLean, Grant D ^a,b   Poppema, Sibrand ^c   Berg, Ann ^d   Longenecker, B Michael ^a,b  

^a Biomira Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d NONE

Author keywords

CA27.29; CD69; Immune suppression; Immunotherapy; MUC 1; Sialyl Tn

Indexed keywords

CANCER VACCINE; CD69 ANTIGEN; CYCLOPHOSPHAMIDE; MUCIN; THERATOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-15-3 ANTIGEN; FEMALE; HEMOCYANIN; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTES; NEOPLASMS; RECEPTORS, INTERLEUKIN-2;

EID: 0029743771     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050287     Document Type: Article

References (33)

1. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S-I, Kim YS (1990) Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66: 1960
2. Werther JL, Rivera-MacMurray S, Tatematsu M, Ito N, Bruckner H, Itzkowitz SH (1991) Sialosyl-Tn: a novel mucin antigen associated with poor prognosis in gastric cancer patients. Proc Am Assoc Cancer Res 32: 241
3. Longenecker BM, Reddish M, Miles D, MacLean GD (1993) Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res 2: 151
4. Yamasha Y, Chung YS, Horie R, Kannagi R, Sowa M (1995) Alterations in gastric mucin with malignant transformation: Novel pathway for mucin synthesis. J Natl Cancer Inst 87: 441
5. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y, Irimura T (1993) Increased expression of sialyl Lewis\ antigen correlates with poor survival of patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 53: 3632
6. Kobayashi H, Terao T, Kawashima Y (1992) Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 10: 95
7. Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-Ha). Cancer Res 51: 1170
8. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A. Millis R, Lamport D (1987) Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47: 5476
9. Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM 1995) Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconjugate J (in press)
10. + activation antigens on peripheral blood PBL populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 61: 470
11. MacLean GD, Reddish MA, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM (1993) Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36: 215
12. Longenecker BM, Reddish M, Koganty R, MacLean GD (1993) Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus DETOX™ adjuvant. Ann NY Acad Science 690: 276
13. Longenecker BM, Reddish M, Koganty R, MacLean GD (1994) Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis: In: RL Ceriani (ed) Antigen and antibody molecular engineering in breast cancer Diagnosis. Plenum, New York, p 105
14. MacLean GD, Reddish MA, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19: 59
15. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM (1992) Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC-I gene. J Tumor Marker Oncol 7: 19
16. Jensen JL, MacLean GD, Suresh MR, Almeida A, Jette D, Lloyd S, Bodnar D, Krantz M, Longenecker BM (1990) Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management. Int J Biol Markers 6: 1
17. Frenette PS, Thirlwell MP, Trudeau M, Thomson DMP, Joseph L, Sinister JS (1994) The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumor Biol 15: 247
18. Cox DR, Oakes D (1984) Analysis of survival data. Chapman & Hall, London
19. Abacus concepts (1994) Survival tools for statview. Abacus Concepts, Berkeley, Calif
20. O'Boyle KP, Zamore R, Adluri S, Cohen A, Kemeny N, Welt S, Lloyd KO, Oettgen HF, Old LJ, Livingston PO (1992) Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res 52: 5663
21. Makar AP, Kristensen GB, Kærn J, Bonner OP, Abeler VM, Tropé CG (1992) Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 79: 1002
22. Longenecker BM, MacLean G (1993) Prospects for mucin epitopes in cancer vaccines. Immunologist 1: 89
23. O'Connell MJ, Ritts RA, Moertel CG, Schutt AJ, Sherwin SA (1989) Recombinant interferon-γ lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9. Cancer 63: 1998
24. Urba WJ, Ewel C, Kopp W, Smith II JW, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, Fenton R, Janik J, Watson T, Beveridge J, Longo DL (1992) Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. Cancer Res 52: 2394
25. Alexander RB, Fitzgerald EB, Mixon A, Carter CS, Jakobsen M, Cohen PA, Rosenberg SA (1995) Helper Tcells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J Immunother 17: 39
26. Berd D, Maguire Jr HC, Mastrangelo MJ, Murphy G (1994) Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother 39: 141
27. Coventry BJ, Neville A, Hillenbrand E (1995) Evidence for local immunosuppression in the microenvironment of breast tumours. In: Abstracts from the Proceedings of the Institut Curie Oncology Conference "Immune cell reactivity of anergy in breast tumors", May 3-5, 1995, Paris, France
28. Zimmermann GL, Longenecker BM (1995) Influcence of levels of MUC1 expression on a tumor cell line's metastatic potential. In: Proceedings of the 9th International Congress of Immunology, July 23-29, 1995, San Francisco, Calif.
29. Bresalier RS, Niv Y, Byrd JC, Dun Q-Y, Toribara NW, Rockwell RW, Dahiya R, Kim YS (1991) Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 87: 1037
30. Wiel-van Kamenade E van de, Ligtenberg MJL, Boer AJ de, Buijs F, Vos HL, Melief CJM, Hilkens J, Figdor CG (1993) Episialin (MUC1) inhibits cytotoxic PBL-target cell interaction. J Immunol 151: 767
31. Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159
32. Hayes DF, Silberstein DS, Rodrique SW, Kufe DW (1990) DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody coated targets. J Immunol 145: 962
33. Ogata S, Maimonis PJ, Itzkowitz SH (1992) Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 52: 4741